Company news
Entropy Neurodynamics Limited (ASX:ENP) news
Entropy Neurodynamics Limited news releases on 6ix. Latest, Oct 6, 2026: TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
Press releases & updates
TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
October 6, 2026
All Patients Improve, 50% Achieve 12-Week BED Remission
September 13, 2026
Appendix 4E and 2026 Annual Report
August 27, 2026
Entropy Advances TRP-8803 to US Phase 2 in Depression
August 25, 2026
TRP 8803 manufacturing secured for Phase 2/3 advancement
August 18, 2026
72 patient multi-indication trial approved to fast track TRP-8803 commercialisation
August 4, 2026
72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
August 3, 2026
South Africa Grants ENP Broad Fibromyalgia Patent to 2043
July 19, 2026
100% Clinical improvement, 50% Remission in BED study
July 6, 2026
DSMB Clears TRP 8803 to Advance to Cohort 2
June 14, 2026
Entropy completes Cohort 1 dosing in BED trial
June 1, 2026
Entropy files new US patent for IBS program
May 4, 2026
TRP 8802 delivers 75% breakthrough response in IBS
May 3, 2026
TRP-8803 delivers repeatable, high-intensity effect
April 13, 2026
FY25 R&D Tax Incentive received
March 4, 2026
Cohort 1 enrolment achieved for TRP-8803 BED Trial
March 2, 2026
Appendix 4D and Half Year Report for period 31 Dec 2025
February 26, 2026
Australian Patent Secures TRP 8803 Platform to 2042
February 11, 2026
Quarterly Activities Report and Appendix 4C
January 29, 2026
First TRP-8803 BED patient shows broad clinical improvement
January 21, 2026
TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
January 12, 2026
$847,186 R&D Tax Incentive received
December 18, 2025
First BED patient completes second TRP-8803 infusion
December 15, 2025
First patient successfully dosed in TRP 8803 BED trial
December 1, 2025
BED trial accelerates - enrolment grows, dosing in two weeks
November 17, 2025
$6.1m in new funding to accelerate clinical development
November 4, 2025
Trading Halt
November 2, 2025
First patient enrolled in Binge Eating Disorder Trial
October 13, 2025
Appendix 4E and 2025 Annual Report
August 28, 2025
Landmark EEG Biomarker Agreement for Precision Psychiatry
August 20, 2025
$2.6m in non-dilutive capital funding secured
August 11, 2025
Patient recruitment for world first TRP-8803 trial underway
July 20, 2025
Binge Eating Disorder Trial receives Human Ethics approval
June 22, 2025
TRP-8803 BED trial to commence with Swinburne this quarter
April 9, 2025
Appendix 4D and Half Year Report for period 31 Dec 2024
February 26, 2025
Positive interim results in Phase 2a TRP-8802 IBS trial
December 17, 2024
Phase 1b extension results meet study objectives
December 15, 2024
Phase 1b determines optimal parameters for TRP-8803 use
November 18, 2024
$6m funding to fast track TRP-8803 clinical trial strategy
October 29, 2024
Pause in Trading
October 27, 2024
TRP-8803 doses deemed safe by SRC following phase 1b study
October 17, 2024
Preliminary Final Report Reporting Adjustments
September 30, 2024
Appendix 4E Preliminary Final Report
August 29, 2024
Completion of patient dosing in maiden TRP-8803 trial
August 25, 2024
Positive Phase 2a fibromyalgia results across all patients
August 11, 2024
Maiden dosing of TRP-8803 completed in global first
July 1, 2024
Reinstatement to Quotation
May 28, 2024
Results of 2024 General Meeting
April 11, 2024
Disclosure Document - Replacement Prospectus
March 28, 2024
Disclosure Document - Prospectus
March 14, 2024